Search for Predictive Markers of Efficacy of ESAs in Patients With Non-myeloid Malignancies or Myelodysplastic Syndrome

Study Overview
=================
Brief Summary
-----------------
Anemia is common among cancer patients and the treatment of choice is now Erythropoiesis-Stimulating Agents (ESAs). However, some patients do not respond to treatment. The purpose of this study is to evaluate the predictive value of endogenous erythropoietin rate on the response to erythropoietin beta. First, by confirming the predictive value of endogenous erythropoietin observed / predicted ratio on this response. Then if it is confirmed by establishing the optimal value of this ratio.

Detailed Description
-----------------
Anemia is common among cancer patients and the treatment of choice is now Erythropoiesis-Stimulating Agents (ESAs). However, some patients do not respond to treatment. Thus, only 50-60% of patients with multiple myeloma or non-Hodgkin lymphoma respond to ESAs. The purpose of this study is to evaluate the predictive value of endogenous erythropoietin rate on the response to erythropoietin beta. First, by confirming the predictive value of endogenous erythropoietin observed / predicted ratio on this response. Then if it is confirmed by establishing the optimal value of this ratio.

Official Title
-----------------
Search for Predictive Markers of Efficacy of Epoetin Beta (NEORECORMON) in the Treatment of Anemia in Patients With Non-myeloid Malignancies Receiving Chemotherapy or Myelodysplastic Syndrome

Conditions
-----------------
Anemia, Myelodysplastic Syndromes, Hemopathies

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients over 18 patients with non-myeloid haemopathy receiving chemotherapy or myelodysplastic syndrome indication of ESAs therapy with Hb < 11g/dl Exclusion Criteria: uncontrolled hypertension anemia due to deficiency pregnant and lactating women patient who received treatment with erythropoiesis-activating factors in the two months preceding inclusion

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| response to erythropoietin | Complete response : increase of 2g/dl of erythropoietin rate or stopping of transfusion requirements. Partial response : increase of 1 to 2g/dl rate of erythropoietin or 50% reduction of transfusion requirements. | 12 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| endogenous erythropoietin rate |  | Within 8 days before inclusion | 
| hemoglobin rate | Weeks 0 = first ESAs injection | Weeks 0,4,8 and 12 | 
| Number of transfusions during the duration of the study |  | 12 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
anemia, non-myeloid haemopathy, myelodysplastic syndrome, Erythropoiesis stimulating agents, predictive markers